HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The rationale for mTOR inhibition in epithelial ovarian cancer.

Abstract
The AKT/mTOR signaling pathway is frequently overexpressed in human epithelial ovarian cancer and an attractive target for therapy. In vivo mouse models were confirmative for in vitro findings, where the administration of mTOR inhibitors in ovarian cancer xenografts showed antitumoral as well as antiangiogenic effects. Phase I - II trials are now ongoing with mTOR inhibitors in ovarian cancer patients, some in combination with conventional cytotoxic agents. If further development of mTOR inhibition in ovarian cancer is pursued, studying combinations of mTOR inhibitors with other new targeted therapies would be of interest. mTOR inhibitors in the adjuvant setting could have potential, since, for the moment, there is no standard maintenance therapy in ovarian cancer. A crucial challenge will be to identify strong predictive biomarkers. This review highlights the rationale for the use of mTOR inhibitors in ovarian cancer and summarizes the available preclinical findings.
AuthorsXuan Bich Trinh, Peter A van Dam, Luc Y Dirix, Peter B Vermeulen, Wiebren A A Tjalma
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 18 Issue 12 Pg. 1885-91 (Dec 2009) ISSN: 1744-7658 [Electronic] England
PMID19888868 (Publication Type: Journal Article, Review)
Chemical References
  • Antibiotics, Antineoplastic
  • Enzyme Inhibitors
  • Intracellular Signaling Peptides and Proteins
  • MTOR protein, human
  • mTOR protein, mouse
  • Protein Serine-Threonine Kinases
  • TOR Serine-Threonine Kinases
  • Sirolimus
Topics
  • Animals
  • Antibiotics, Antineoplastic (therapeutic use)
  • Clinical Trials as Topic
  • Drug Screening Assays, Antitumor
  • Enzyme Inhibitors (therapeutic use)
  • Female
  • Humans
  • Intracellular Signaling Peptides and Proteins (drug effects, metabolism)
  • Models, Biological
  • Neoplasms, Glandular and Epithelial (drug therapy, metabolism)
  • Ovarian Neoplasms (drug therapy, metabolism)
  • Protein Serine-Threonine Kinases (drug effects, metabolism)
  • Signal Transduction (drug effects)
  • Sirolimus (analogs & derivatives, therapeutic use)
  • TOR Serine-Threonine Kinases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: